Aarti Drugs Q1 FY27 results: audited, Rs 2.09 Cr CWIP write-off

Exceptional ItemResults View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹423.00

prior close

₹424.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-5.0% vs market

Pharmaceuticals peers, median of 163sector+1.0%-4.6% vs sector

On the reaction day the stock moved 5.0 pts less than Nifty Microcap 250 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-3.0

15m

-2.7

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6+1.3-5.0+1.0-4.6

Next day

-2.4+1.8-4.1+0.8-3.2

-2.7+3.1-5.7+0.3-3.0

-2.8+3.5-6.3+0.7-3.6

-1.1+3.5-4.6+1.5-2.6

+0.0+3.4-3.4+1.3-1.3

+2.4+3.6-1.3+1.5+0.9

15d

-0.1+4.9-4.9+0.9-1.0

+0.5+4.4-3.9+1.7-1.2

-2.0+2.9-4.9+1.9-3.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Drugs filed audited Q1 FY27 results (quarter ended June 30, 2026). Total income around Rs 63,168 lakh standalone and Rs 72,030 lakh consolidated. Standalone PAT near Rs 4,496 lakh; consolidated PAT about Rs 5,526 lakh. Exceptional item of Rs 2.09 crore is a write-off of Capital Work-in-Progress for the admin building at E1, not part of routine expansion. Statutory auditor Gokhale and Sathe issued an unmodified (clean) opinion. Single segment: pharmaceuticals.

Likely market impact

CWIP write-off is a one-time non-cash hit. Clean audit opinion supports credibility. Watch margin trajectory.